Potent, reversible EGFR tyrosine kinase inhibitor
Erlotinib hydrochloride is a reversible, potent EGFR tyrosine kinase inhibitor (IC50 = 2 nM); it reduces EGFR autophosphorylation in intact tumor cells (IC50 = 20 nM). Erlotinib is selective for cell lines showing PC-9 and H3255 mutations (IC50 values are 7 and 12 nM, respectively, sparing wild-type and T790 mutant EGFR. Erlotinib shows antiproliferative effects in cancer cell lines
in vitro
and promotes differentiation of urothelial organoids. Orally bioavailable.
| Marque | Tocris Bioscience |
|---|---|
| Réf. B-LABO | BL-RE-124879 |
| Réf. fabricant | 18739766 |
| Nom chimique ou matériau | N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
| CAS | 183319-69-9 |
| Quantité | 50 mg |
| Cible | EGF Receptor Inhibitors |
| Formule moléculaire | C<sub>22</sub>H<sub>23</sub>N<sub>3</sub>O<sub>4</sub>.HCl |
| Pureté | 0.98 |
